- Home
- IONS vs DLB Comparison
IONS vs DLB Comparison
Compare IONS & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- DLB
- Stock Information
- Founded
- IONS 1989
- DLB 1965
- Country
- IONS United States
- DLB United States
- Employees
- IONS N/A
- DLB N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- DLB Multi-Sector Companies
- Sector
- IONS Health Care
- DLB Miscellaneous
- Exchange
- IONS Nasdaq
- DLB Nasdaq
- Market Cap
- IONS 6.8B
- DLB 6.2B
- IPO Year
- IONS 1991
- DLB 2005
- Fundamental
- Price
- IONS $72.93
- DLB $64.39
- Analyst Decision
- IONS Strong Buy
- DLB Strong Buy
- Analyst Count
- IONS 21
- DLB 5
- Target Price
- IONS $80.71
- DLB $96.60
- AVG Volume (30 Days)
- IONS 2.9M
- DLB 525.6K
- Earning Date
- IONS 10-29-2025
- DLB 11-18-2025
- Dividend Yield
- IONS N/A
- DLB 2.04%
- EPS Growth
- IONS N/A
- DLB 24.38
- EPS
- IONS N/A
- DLB 2.71
- Revenue
- IONS $966,957,000.00
- DLB $1,346,912,000.00
- Revenue This Year
- IONS $27.96
- DLB $6.77
- Revenue Next Year
- IONS $2.33
- DLB $4.41
- P/E Ratio
- IONS N/A
- DLB $23.82
- Revenue Growth
- IONS 20.41
- DLB 6.94
- 52 Week Low
- IONS $23.95
- DLB $64.24
- 52 Week High
- IONS $76.78
- DLB $89.66
- Technical
- Relative Strength Index (RSI)
- IONS 55.70
- DLB 35.82
- Support Level
- IONS $68.22
- DLB $64.38
- Resistance Level
- IONS $74.50
- DLB $67.17
- Average True Range (ATR)
- IONS 3.36
- DLB 1.15
- MACD
- IONS -0.55
- DLB 0.12
- Stochastic Oscillator
- IONS 64.72
- DLB 8.75
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.